Eloxx Pharmaceuticals, Inc.

About Eloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals is a biotechnology company focused on leveraging innovative technology platforms to develop novel small molecule genetic therapies aimed at transforming genetic diseases by correcting nonsense mutations and ribosomal mutations.

Products & Services

CELX-02:A treatment for Alport Syndrome, a rare kidney disease.

Turbo-ZM™ RMAs:Ribosome Modulating Agents as part of their platform technology for genetic therapies.

Eukaryotic Ribosomal Selective Glycosides (ERSGs):A platform technology focused on transforming genetic diseases.

Pipeline for Nonsense Mutation Alport Syndrome:Therapies targeting Alport Syndrome caused by nonsense mutations.

Pipeline for Nonsense Mutation RDEB/JEB:Therapies for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and Junctional Epidermolysis Bullosa (JEB) caused by nonsense mutations.

exaluren

ZKN-013

Specialties

Small Molecule Genetic Therapies Nonsense Mutation Therapies Ribosomal Mutation Therapies Rare Kidney Diseases Genetic Disease Transformation nonsense mutation readthrough rare kidney diseases Alport syndrome ADPKD

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 66000000 MR: - FA: $66.0 million FAN: 66000000	D: 2026-06-08 FD: 2026-06-08	-
2	RT: Debt T: - FT: Debt	A: 3200000 MR: - FA: $3.2 million FAN: 3200000	D: 2024-07-11 FD: 2024-07-11	-
3	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 2000000 MR: - FA: approximately $2 million FAN: 2000000	D: 2023-09-19 FD: 2023-09-19	1 investors

Public Offering Latest

2026-06-08

$66.0M

Debt 2024-07-11

$3.2M

Registered Direct Offering 2023-09-19

$2.0M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Sumit Aggarwal

President & Chief Executive Officer

D

Daniel E. Geffken

Interim Chief Financial Officer

R

Roger Clark

VP, Head of Discovery Sciences

T

Teji Singh

VP, Head of Clinical Development

J

John Woolford

VP, Head of Corporate Development

N

Nina Kjellson

General Partner, Canaan Partners

View 6 more team members with Pro

Unlock Full Team Directory

Recent News